Cargando…

Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients

Ferric pyrophosphate citrate (FPC) is a water-soluble iron salt administered via dialysate to supply iron directly to transferrin. The PRIME study tested whether treatment with FPC could reduce prescribed erythropoiesis-stimulating agent (ESA) use and maintain hemoglobin in hemodialysis patients. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Ajay, Lin, Vivian, Guss, Carrie, Pratt, Raymond, Ikizler, T Alp, Besarab, Anatole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653585/ https://www.ncbi.nlm.nih.gov/pubmed/26154926 http://dx.doi.org/10.1038/ki.2015.203

Ejemplares similares

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

Physicochemical characterization of ferric pyrophosphate citrate
por: Gupta, Ajay, et al.
Publicado: (2018)

Ferric pyrophosphate citrate: interactions with transferrin
por: Pratt, Raymond, et al.
Publicado: (2018)

Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease
por: Gan, Liangying, et al.
Publicado: (2022)

Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022)

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Conversion from acetate dialysate to citrate dialysate in a central delivery system for maintenance hemodialysis patients
por: Park, Eun ji, et al.
Publicado: (2019)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Effects of Acetate-Free Citrate Dialysate on Glycoxidation and Lipid Peroxidation Products in Hemodialysis Patients
por: Masuda, Atsumi, et al.
Publicado: (2012)

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients
por: Rivara, Matthew B., et al.
Publicado: (2015)

Calcium Repletion and Regional Citrate Anticoagulation in Hemodialysis and Hemodiafiltration: Using Dialysate Calcium to Modify Hypocalcemia
por: Dorie, Justin R., et al.
Publicado: (2021)

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model
por: Mutell, Richard, et al.
Publicado: (2013)

Antiviral effects of ferric ammonium citrate
por: Wang, Hongbin, et al.
Publicado: (2018)

Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia
por: Pergola, Pablo E., et al.
Publicado: (2018)

The metabolomic differential plasma profile between dialysates. Pursuing to understand the mechanisms of citrate dialysate clinical benefits
por: Broseta, José Jesús, et al.
Publicado: (2022)

Intestinal Absorption Study of a Granular Form of Ferric Pyrophosphate
por: Micheletto, Marta, et al.
Publicado: (2022)

Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study
por: Yessayan, Lenar, et al.
Publicado: (2014)

Is Anticoagulation Discontinuation Achievable with Citrate Dialysate during HDF Sessions?
por: Dolley-Hitze, Thibault, et al.
Publicado: (2016)

Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study
por: Ficociello, Linda H, et al.
Publicado: (2021)

Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)

Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis
por: Fuertinger, Doris H., et al.
Publicado: (2018)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
por: Ganz, Tomas, et al.
Publicado: (2019)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial
por: Hanudel, Mark R., et al.
Publicado: (2022)

Citrate anticoagulation realized as CVVHD using a newly designed dialysate solution
por: Morgera, S, et al.
Publicado: (2006)

Success of Pregnancy in a Patient on High-Volume Hemodiafiltration with Citrate-Acidified Dialysate
por: Pellé, Gaëlle, et al.
Publicado: (2023)

Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
por: Darsonval, Astrid, et al.
Publicado: (2017)

Impact of acetate- or citrate-acidified bicarbonate dialysate on ex vivo aorta wall calcification
por: Villa-Bellosta, Ricardo, et al.
Publicado: (2019)

Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory?
por: Medrano, Chloé, et al.
Publicado: (2021)

Impact of Acetate versus Citrate Dialysates on Intermediary Metabolism—A Targeted Metabolomics Approach
por: Broseta, José Jesús, et al.
Publicado: (2022)

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
por: Bernieh, Bassam, et al.
Publicado: (2014)

Reduction of costs for anemia-management drugs associated with the use of ferric citrate
por: Thomas, Anila, et al.
Publicado: (2014)

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014)

Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
por: Hain, Debra J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fjfi2ea542mbt0ji8n5qr9qtfb